Results 31 to 40 of about 1,571,497 (188)

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

Haematologica, 2012
Early mortality in acute promyelocytic leukemia has been reported to occur in less than 10% of patients treated in clinical trials. This study reports the incidence and clinical features of acute promyelocytic leukemia patients treated at Stanford ...
James Scott McClellan, Holbrook E. Kohrt, Steven Coutre, Jason R. Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros   +6 more
doaj   +1 more source

Targeting the MLL complex in acute leukemia [PDF]

, 2014
Chromosomal rearrangements leading mostly to fusion oncoproteins of the Mixed Lineage Leukemia (MLL) gene occur in about 10% of all patients with acute leukemia and are often associated with poor clinical outcome, emphasizing the need for new treatment ...
Méreau, Hélène
core   +1 more source

Frontline Management of Acute Promyelocytic Leukemia

, 2023
In the frontline management of acute promyelocytic leukemia (APL), prevention of early deaths and the selection of the optimal frontline induction strategies incorporating arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are the more important ...
Singh, Gill Harinder Harry
core   +1 more source

A giant thrombus in the right atrium of a patient with acute promyelocytic leukemia M3

Radiology Case Reports, 2023
Acute promyelocytic leukemia is a special type of acute myeloid leukemia. Patients with this disease are at high risk of complications. Right atrial thrombosis is a rare but potentially serious complication.
Pham Ngoc Thach, MD, Ho Tran Ban, MD, Huynh-Thi Vu Quynh, MD, Tran-Thi Thanh, MD, Phan Thao Nguyen, MD, Trinh Nguyen Ha Vi, MD, Tran Ba Hieu, MD, Nguyen Duc Chinh, MD, Tran Hoa, MD, Bui The Dung, MD, Nguyen Minh Duc, MD   +10 more
doaj   +1 more source

Cancer treatment pathways: AML a detailed costing study example [PDF]

, 2011
Background: AML is one of the most common and acute diseases among the types of leukaemia. The treatment costs for AML/APML are considerably high as it involves the use of expensive treatments (such as stem cell transplantation).
WANG, HAN-I
core   +6 more sources

Preserved cellular immunity in smoldering acute leukemia [PDF]

, 1976
"Smoldering acute leukemia", a variant of acute myelogenous leukemia, has been recognized with frequent incidence in recent years. This is chracterized by benign clinical course, poor physical findings, leukopenia and mild anemia in the ...
Hironobu Toki, Toki, Hironobu
core   +1 more source

Acute myeloid leukemia with fusion resembling acute promyelocytic leukemia, initially presenting as sweet syndrome: A case report and literature review

Journal of International Medical Research
Some subtypes of acute myeloid leukemia share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia but lack a promyelocytic leukemia–retinoic acid receptor alpha fusion gene.
Huan Liu, Guo-Xia Liu, Feng-Hai Liu, Shu-Guo Wang   +3 more
doaj   +1 more source

Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report

Journal of Medical Case Reports, 2012
Introduction In the relapsed setting, arsenic trioxide remains the backbone of treatment. Scant literature exists regarding treatment of relapsed acute promyelocytic leukemia in patients with renal failure.
Emmons Gregory S, Steingart Richard H, Stewart James A, Mertens Wilson C   +3 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source